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Abstract
Inflammatory angiogenesis and vascular remodeling play key roles in the chronic inflammatory skin disease psoriasis, but
little is known about the molecular mediators of vascular activation. Based on the reported elevated mRNA levels of the
angiogenic chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 in psoriasis, we investigated the
relevance of the SDF-1/CXCR4 axis in two experimental models of chronic psoriasis-like skin inflammation. The cutaneous
expression of both SDF-1 and CXCR4 was upregulated in the inflamed skin of K14-VEGF-A transgenic mice and in
imiquimod-induced skin inflammation, with expression of CXCR4 by blood vessels and macrophages. Treatment with the
CXCR4 antagonist AMD3100 potently inhibited skin inflammation in both models, associated with reduced inflammatory
angiogenesis and inflammatory cell accumulation, including dermal CD4+ cells and intraepidermal CD8+ T cells. Similar anti-
inflammatory effects were seen after treatment with a neutralizing anti-SDF-1 antibody. In vitro, inhibition of CXCR4 blocked
SDF-1-induced chemotaxis of CD11b+ splenocytes, in agreement with the reduced number of macrophages after in vivo
CXCR4 blockade. Our results reveal an important role of the SDF-1/CXCR4 axis in skin inflammation and inflammatory
angiogenesis, and they indicate that inhibition of the SDF-1/CXCR4 axis might serve as a novel therapeutic strategy for
chronic inflammatory skin diseases.
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Introduction
Psoriasis is a chronic inflammatory skin disease that affects 2%
to 3% of the population worldwide [1]. The major features of
psoriatic skin lesions are the thickening of the epidermis, associated
with enhanced proliferation and aberrant terminal differentiation
of epidermal keratinocytes, and the accumulation of inflammatory
leukocytes, in particular dendritic cells and T cells [2]. There is a
preferential accumulation of CD4+ cells in the dermis and of
CD8+ cells in the epidermis of lesional psoriatic skin [2], and there
are also increased numbers of macrophages whose function in the
disease process is not fully understood [3].
A third – and often overlooked - hallmark of psoriatic skin is
represented by the pronounced inflammatory angiogenesis,
leading to vascular remodeling [4]. This vascular activation is
similar to the blood vessel changes observed in several other
chronic inflammatory diseases, including rheumatoid arthritis,
inflammatory bowel disease and chronic airway inflammation [5–
7]. Vascular endothelial growth factor (VEGF)-A has been
identified as the major angiogenesis factor in psoriatic skin since
its expression is strongly upregulated in lesional epidermis [5], and
the plasma levels of VEGF-A are elevated in psoriasis patients and
correlate with disease severity [8]. Moreover, targeted chronic
overexpression of VEGF-A in the epidermis of mice results in the
spontaneous development of a chronic inflammatory skin disease
that shares many features of human psoriasis [9,10], and inhibition
of VEGF-A signaling inhibited inflammation in different murine
models of psoriasis [9–12]. Together, these results indicate an
important role of VEGF-A and angiogenesis in disease mainte-
nance and progression, but additional factors that target the
vascular system are likely involved.
Several pro-inflammatory chemokines have been reported to
also exhibit angiogenic properties [13,14]. In particular, stromal
cell-derived factor-1 (SDF-1, also known as CXCL12) has been
found to have angiogenic activity in different in vitro and in vivo
systems [15,16], and its primary receptor CXCR4 is expressed by
endothelial cells as well as monocytes and lymphocytes [17,18].
SDF-1 is expressed in several tissues including the skin and the
bone marrow [19], and the SDF-1/CXCR4 axis is involved in a
range of physiological processes such as embryonic development
and stem cell motility [20]. Since VEGF-A upregulates CXCR4 in
cultured human endothelial cells [16], and since elevated mRNA
levels of both SDF-1 and CXCR4, as well as elevated SDF-1
protein levels, have been found in lesional psoriatic skin [21–23],
we hypothesized that the SDF-1/CXCR4 axis might play a
potential role in the pathogenesis of chronic inflammatory skin
diseases including psoriasis.
Therefore, we first investigated the expression of CXCR4 in
human psoriasis and of both SDF-1 and CXCR4 in two
established experimental mouse models of chronic psoriasis-like
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skin inflammation - the keratin 14 (K14)–VEGF-A transgenic
mouse model of induced chronic cutaneous inflammation [9], and
the imiquimod-induced psoriasis-like skin inflammation mouse
model [24,25]. Next, we investigated the potential anti-inflamma-
tory effects of blockade of CXCR4 signaling by systemic treatment
with AMD3100, a specific CXCR4 antagonist [26], in both
inflammation models, and we also studied the effects of a
neutralizing anti-SDF-1 antibody. Our results reveal an important
role of the SDF-1/CXCR4 axis in skin inflammation and
inflammatory angiogenesis, and they indicate that inhibition of
the SDF-1/CXCR4 axis might serve as a novel treatment strategy
for chronic inflammatory skin diseases.
Materials and Methods
Ethics Statement
The collection of specimens from clinically indicated excisions
for this study was explicitly approved by the institutional review
board (Kantonale Ethikkommission Zu¨rich). Informed consent
(both written and verbal) was obtained from patients for the use of
their skin samples in this research project.
Mice and treatments
All mice used in this study were bred and housed in the animal
facility of ETH Zurich. Experiments were performed in accor-
dance with animal protocol 149/2008 and 117/2011 approved by
the local veterinary authorities (Kantonales Veterina¨ramt Zu¨rich).
K14-VEGF-A transgenic mice have been described previously
[10,27]. To induce a psoriasis-like skin inflammation in the ear
skin [9] of these mice, a 2% oxazolone solution (4-ethoxymethy-
lene-2 phenyl-2-oxazoline-5-one; Sigma-Aldrich) in aceton/olive
oil (4:1 vol/vol) was applied topically to the shaved abdomen
(50 ml) and to each paw (5 ml) of 8-weeks old females. Five days
after sensitization (day 0), both ears were challenged by topical
application of 10 ml oxazolone (1%) on each side. Ear thickness
was measured before challenge and repeatedly after challenge
using calipers. Starting on day 7, 10 mg/kg of AMD3100
octahydrochloride hydrate (1,19-[1,4-Phenylenebis(methylene)]-
bis-1,4,8,11-tetraazacyclotetradecaneoctahydrochloride, Sigma-
Aldrich) or PBS (vehicle) was administered subcutaneously into
the loose skin over the neck of the mice for 14 days every 12 hours
(n = 10 per group). The AMD3100 dose was chosen based on
previous studies [28].Additionally, inflamed K14-VEGF-A mice
were treated with 50 mg of a neutralizing mouse anti-mouse SDF-1
monoclonal antibody (MAB310; R&D Systems) or control mouse
IgG (MAB002; R&D Systems), administered i.v. from day 7 to day
21, every second day (n = 7 per group). On day 21, mice were
injected with 300 ml PBS containing 40 mM BrdU (Sigma-
Aldrich) and killed 2.5 h after the injection. Ears and ear draining
lymph nodes (LN) were embedded in optimal cutting temperature
(OCT) compound (Sakura Finetek) or used for FACS analysis (see
Materials and Methods S1 in File S1) and RNA isolation.
In a second model of psoriasis, C57BL/6 wild-type mice (n = 5)
received daily topical applications of imiquimod, using a
commercially available cream (5%) (Aldara: 3 M Pharmaceuti-
cals), on the ear skin for 8 consecutive days AMD3100 treatment
was started 12 h before the first imiquimod treatment and
repeated every 12 hours as described in the section above. Ear
thickness was measured every day, starting before the first
AMD3100 treatment. Ears and ear draining LN were embedded
in OCT or used for RNA isolation. For all mice, the weight of the
ear draining LN was determined.
Immunofluorescence
Tissues were embedded in OCT, frozen on liquid nitrogen, and
7 mm cryostat sections were cut. Specimens were placed on glass
slides, air dried and fixed with aceton for 2 min at 220uC. After
rehydration with 80% methanol at 4uC, the specimens were
washed in PBS and then in PBS with 5% donkey serum and 1%
bovine serum albumin, followed by incubation with the respective
primary antibodies. Standard H&E and immunofluorescence
stainings were performed as described previously [9,29], using
the following antibodies: anti-mouse LYVE-1 (AngioBio), biotin
anti-MECA-32 (BD Biosciences), anti-human von Willebrand
factor (Dako), anti-mouse podoplanin (clone 8.1.1, Developmental
Studies Hybridoma Bank, University of Iowa), anti-mouse keratin
6, anti-loricrin (Covance Research Products), anti-BrdU-Alexa
Fluor 594 (Invitrogen), anti-mouse F4/80 (AbD Serotec), anti-
mouse CD68 (Abcam), anti-mouse CD8 (BD Biosciences) and
anti-mouse CXCR4 (R&D Systems). Alexa Fluor488-, Alexa
Fluor594- and Alexa Fluor647-coupled secondary antibodies and
Hoechst 33342 were purchased from Invitrogen.
Immunohistochemistry
Immunohistochemistry was performed on 2 mm paraffin
sections of normal human skin (n = 8) and of lesional psoriatic
skin (n = 8), using an anti-human CXCR4 antibody (R&D
Systems) or control mouse IgG (Sigma) followed by a biotinylated
anti-mouse secondary antibody (Vector). The Vectastain ABC and
the AEC (3-amino-9-ethylcarbazole) substrate kits (Vector) were
used for chromogenic detection.
Computer-assisted morphometric analyses
Double immunofluorescence stains of ear sections for MECA-
32 and LYVE-1 were examined, and computer-assisted analysis of
digital images were performed using an in-house designed ImageJ
macro. The average number of LYVE-1+ lymphatic vessels and
MECA-32+ blood vessels per millimeter epidermal basement
membrane and the average size of vessels were determined in the
area between cartilage and epidermis of one ear half. The results
are expressed as vessel number per millimeter of epidermal
basement membrane (excluding follicular structures) [29] and not
as vessel number per area because the formation of inflammatory
edema (increase in area) would confound the vessel number if it
were calculated per area. To quantify CD8+ and BrdU+ cell
numbers per millimeter of epidermal basement membrane, images
of four individual fields of view were acquired per sample.
Quantification of F4/80+, CD68+ and CXCR4+ areas was done
by measuring the immunostained areas using gray-scale detection
with a fixed threshold in ImageJ (National Institutes of Health,
Bethesda) and was expressed as positive stained area per region of
interest (one ear half).
Image acquisition
Stainings were examined using an Axioskop2 mot plus
microscope (Carl Zeiss, Inc.), equipped with an AxioCamMRc
camera and a Plan-APOCHROMAT 10x/0.45 NA objective
(Carl Zeiss, Inc.) Images were acquired using Axio Vision Version
4.4 software (Carl Zeiss). Confocal images were acquired with a
LSM710 FCS confocal microscope and ZEN software (Zeiss, Jena,
Germany) and were processed with IMARIS software (Verstion
7.1.1, Bitplane AG, Zu¨rich, Switzerland).
Quantitative real-time RT-PCR
Total cellular RNA was isolated from mouse ears using a
TissueLyser, stainless steel beads, and the RNeasy Mini kit
SDF-1/CXCR4 in Skin Inflammation
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(QIAGEN). 1 mg RNA was used to generate cDNA using the
High-Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems). The expression of mouse CXCR4, SDF-1, CXCR7,
CXCL3, CCL20, S100a7/8 was investigated by SYBR Green
real-time reverse-transcribed polymerase chain reaction (RT-
PCR) using the AB7900 HT Fast Real-Time PCR System
(Applied Biosystems) and was quantified using the 22DDCt method
[30]. The primers for mouse CXCR4, SDF-1, CXCR7, CXCL3,
CCL20, S100a7/a8 were custom-made oligonucleotide primers
(Microsynth, Switzerland). Each reaction was run with b-actin as a
reference gene, and all data were normalized based on the
expression levels of b-actin; n= 5 per group.
Isolation of CD11b+ splenocytes and transwell migration
assays
Splenic CD11b+ cells were isolated from wildtype FVB mice by
positive selection using mouse CD11b MicroBeads (Miltenyi
Biotech). CXCR4 expression of CD11b+ splenocytes was analyzed
by flow cytometry. A single cell suspension of CD11b+ splenocytes
was stained at 4uC for 30 minutes with PE-labeled rat anti-mouse
CXCR4 antibody (eBioscience) or isotype control antibody
(BioLegend). FACS was performed on a BD FACSCanto (BD
Biosciences) using FACSDiva software. Data were analyzed with
FlowJo software. Transwell migration assays were performed using
polycarbonate 5 mm pore size-membrane 24-well plates (Corning
Life Sciences). When AMD3100 was tested, cells were pre-
incubated for 30 minutes with the compound. 46105 CD11b+
splenocytes were seeded in 0.2% BSA containing medium
(DMEM, Invitrogen) into the upper part of the transwell insert,
which was coated with 10 mg/ml fibronectin (Millipore) on the
lower side and blocked with 100 mg/ml BSA as described [31].
Cells were allowed to migrate to the lower chamber containing
either 0.2% BSA, additional recombinant SDF-1 (10, 100 or
500 ng/ml; Peprotech) alone or in combination with anti-SDF
antibody or control IgG antibodies (10 mg/ml) for 3.5 h. After the
incubation time, non-migrated cells were mechanically removed
and the migrated cells were stained with Hoechst. Five images per
insert were taken and nuclei from 3 wells per condition were
counted using ImageJ.
Detection of endothelial CXCR4 expression by FACS
Primary human dermal blood vascular endothelial cells (BEC)
and lymphatic endothelial cells (LEC) were isolated from neonatal
human foreskins as previously described [32]. BECs were cultured
in endothelial basal medium (EBM; Lonza), supplemented with
20% fetal bovine serum (FBS; Invitrogen), 2 mM L-glutamine,
antibiotic-antimycotic solution (Invitrogen), and 10 mg/ml hydro-
cortisone (Sigma). LECs were cultured in the same medium with
additional N6,2-O-dibutyryladenosine-39,59-cyclic monophos-
phate (25 mg/mL; Sigma). Cells were used at passage 6. For
FACS analyses, BECs and LECs were stained with PE-labeled
anti-human CXCR4 (eBioscience) or isotype control antibody
(BioLegend).
Statistical analyses
Statistical analyses were performed using Prism version 4.0
(GraphPad Software, Inc). Data are shown as mean 6SD or
6SEM as indicated and were analyzed with a 2-tailed, unpaired
Student’s t-test whentwo groups were compared, a one-way
ANOVA with Bonferroni post-test when more than two groups
were compared, and a two-way Anova with Bonferroni post-test
for repeated measurements. Homogeneity of variances was
assessed using Levene’s test, and normalized distribution was
assessed using Q-Q-plots. Differences were considered statistically
significant when P#0.05.
Results
Chronic skin inflammation leads to up-regulation of
CXCR4 and SDF-1 and to accumulation of CXCR4+ cells
We first investigated whether CXCR4 might play a role in
human psoriasis. To this end, we performed immunohistochemical
stains for CXCR4 on sections of normal human skin and of
psoriatic skin lesions. In normal human skin, the CXCR4
expression was largely restricted to epidermal keratinocytes
(Fig. 1A). In comparison, in psoriatic lesional skin, CXCR4 was
also expressed on a large number of infiltrating single cells, mostly
represented by macrophages. No staining was observed with
isotype matched control IgG. Additionally, CXCR4 expression
was also seen on some vascular endothelial structures. The
number of CXCR4+ cells in the dermis, was significantly increased
(+652%, P,0.001) in psoriatic skin compared to normal human
skin (Fig. 1B). Next, we investigated whether the SDF-1/CXCR4
axis might also be involved in the experimental skin inflammation
model of hemizygous K14-VEGF-A transgenic mice. These mice
develop a chronic, psoriasis-like skin inflammation after sensitiza-
tion and challenge with the contact sensitizer oxazolone [9]. Real-
time RT-PCR analyses revealed a significantly increased expres-
sion of CXCR4 (2.0-fold, P,0.001) and SDF-1 (1.7-fold,
P,0.001) in the inflamed (21 days after oxazolone challenge)
ear skin of K14-VEGF-A transgenic mice as compared to the
uninflamed skin of wild-type mice (Fig. 1C). There was also a slight
upregulation of CXCR4 and SDF-1 in the non-inflamed skin of
the transgenic mice compared to wild-type mice, likely due to the
reported proinflammatory status of these mice [27].
In contrast, no significant differences in the expression of
CXCR7, another SDF-1 receptor, were found between wild-type
skin, uninflamed and inflamed skin of K14-VEGF-A transgenic
mice, although levels were slightly lower under inflamed condi-
tions (Fig. 1C). Immunofluorescence stainings showed that in the
inflamed skin of K14-VEGF-A transgenic mice, more cells
expressed CXCR4 than in uninflamed skin of K14-VEGF-A
transgenic and of wild-type mice (Fig. 1D). Quantitative image
analyses revealed that the percentage of tissue area that stained
positively for CXCR4 was significantly increased in the inflamed
ear skin of K14-VEGF-A transgenic mice as compared with
wildtype mice (384%, P,0.001) and uninflamed K14-VEGF-A
transgenic mice (189%, P,0.001) (Fig. 1E).
Blockade of CXCR4 reduces chronic skin inflammation
and inflammatory angiogenesis
We next investigated the effects of AMD3100, a selective
CXCR4 antagonist [26], on the inflammatory response. K14-
VEGF-A transgenic mice were sensitized with oxazolone (day -5)
and challenged 5 days later by topical application of oxazolone on
both sides of the ears. 7 days after challenge, the mice received s.c.
injections of AMD3100 or PBS every 12 hours. On day 21, the
mice were analyzed, 12 hours after receiving the last injection
(Fig. 2A). AMD3100 treatment significantly reduced edema
formation in the ears already after 2 days of treatment (day 9;
231.85%; P,0.001) as compared with control PBS-injected mice
(Fig. 2B). The anti-inflammatory effect of AMD3100 was reflected
by the significantly reduced weight of the ear draining LN after 14
days of AMD3100 treatment (229.76%; P,0.001; Fig. 2C).
Accordingly, ear redness was also reduced after 3 (day 10) and 14
days (day 21) of AMD3100 treatment (Fig.2 D-G).
SDF-1/CXCR4 in Skin Inflammation
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To study potential changes in cutaneous vascularization, we
next performed immunostains for the blood vessel marker MECA-
32 and for the lymphatic vessel marker LYVE-1 (Fig. 3A-B). The
number of blood vessels was significantly lower in the skin of
AMD3100-treated mice than in control mice (-19.94%; p,0.05;
Fig. 3C). In contrast, there was no significant change in blood
vessel size, lymphatic vessel number or lymphatic vessel size (data
not shown). These results are in agreement with our in vitro
findings, obtained by FACS analysis of cultured human cells, that
CXCR4 is a blood vessel endothelial cell specific gene that is not
expressed by lymphatic endothelial cells (Fig. 3D–E). Immunoflu-
orescence stains of inflamed ear skin revealed that CXCR4 was
indeed expressed by von Willebrand factor-positive blood vessels
but not by podoplanin-positive lymphatic vessels (Fig. 3F).
Neutralization of SDF-1 reduces chronic skin
inflammation and inhibits leukocyte migration towards
SDF-1 in vitro to a similar extent as AMD3100. Because
blockade of CXCR4 inhibited chronic skin inflammation, we next
investigated whether neutralization of the CXCR4 ligand SDF-1
might have comparable effects. To this end, we sensitized and
challenged hemizygous K14-VEGF-A transgenic mice as de-
scribed above. At 7 days after challenge, the mice were treated
every second day by i.v. injection of an anti-SDF-1 antibody or of
isotype-matched IgG. Mice were analyzed two days after the last
antibody injection (day 21; Fig. 4A). A significant reduction of ear
swelling was observed within 2 days of anti-SDF-1 antibody
treatment, as compared with control IgG injection (day 9;
215.29%; P,0.001; Fig. 4B–D). The anti-inflammatory effect
of the anti-SDF-1 antibody was reflected by the reduced weight of
ear draining LNs at day 21 (217.81%; P,0.01; Fig. 4E).
Immunofluorescence analyses of inflamed ear skin showed a
significant reduction of the macrophage-positive stained area
(227.90%, P,0.01) in anti-SDF-1-treated mice as compared to
IgG-treated mice (Figure 4 F–H). SDF-1 neutralization also
significantly reduced the size of blood vessels (236.78%, P,0.05)
and slightly reduced the number of blood vessels in comparison to
IgG (219.9%, P= 0.08) (Figure 4I–L).
To further investigate the role of the SDF-1/CXCR4 axis in
leukocyte migration, we next performed an in vitro leukocyte
chemotaxis assay using CD11b+ splenocytes. As shown by FACS
Figure 1. Increased number of CXCR4+ cells in human psoriatic skin and up-regulation of CXCR4 and SDF-1 in experimental chronic
skin inflammation. (A–B) Immunohistochemistry revealed, that in normal human skin, CXCR4 is mainly expressed in the epidermis. In psoriatic skin,
CXCR4 is also expressed on a big number of infiltrating cells. Quantitative image analysis showed that significantly more CXCR4+ cells were present in
the dermis of psoriatic skin lesions (n = 8) than in normal human skin (n = 8). Staining with isotype matched control IgG confirmed the specificity of
the CXCR4 staining. Scale bar represents 100 mm. ***P,0.001. (C) Real-time RT-PCR analysis of RNA obtained from whole ear skin extracts of inflamed
K14-VEGF-A transgenic mice (day 21 after oxazolone challenge), untreated K14-VEGF-A transgenic, and wild-type mice (n = 5 per group). The
expression of CXCR4 and SDF-1 was significantly up-regulated in uninflamed K14-VEGF-A transgenic mouse skin compared to wild-type mice and was
further increased in the inflamed skin of K14-VEGF-A transgenic mice. The expression of CXCR7 was slightly lower in the skin of K14-VEGF-A
transgenic mice. (D–E) Immunofluorescence stains for CXCR4 revealed that inflamed K14-VEGF-A transgenic mice have a significantly increased
CXCR4+ tissue area as compared with uninflamed K14-VEGF-A transgenic mice and wild-type mice. Scale bar represents 100 mm. Data represent mean
6 SD. *P,0.05; ***P,0.001. ns, not significant.
doi:10.1371/journal.pone.0093665.g001
SDF-1/CXCR4 in Skin Inflammation
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Figure 2. Inhibition of CXCR4 reduces edema formation in chronic skin inflammation. (A) Hemizygous K14-VEGF-A transgenic mice
(n = 20) were sensitized with 2% oxazolone on day -5 and challenged on day 0 by topical application of 1% oxazolone on the ears. Starting on day 7,
mice received s.c injections of AMD3100 (CXCR4-antagonist) or PBS (vehicle) (n = 10 per group) every 12 hours. Two independent experiments were
performed. (B) Treatment with AMD3100 (g) reduced ear swelling, as compared with PBS-treated controls (%) Data represent mean6SEM. (C)
Reduced weight of ear draining LN after 14 days of AMD3100 treatment (day 21), as compared with PBS-injected mice. Data represent mean6SD.
***P,0.001. (D-G) AMD3100-treated animals showed reduced ear redness on day 10 (E) and day 21 (G) as compared to PBS-treated animals (D,F).
doi:10.1371/journal.pone.0093665.g002
Figure 3. Inflammatory angiogenesis is reduced by inhibition of CXCR4. (A–B) Representative fluorescent images of MECA-32+ blood
vessels (red) and LYVE-1+ lymphatic vessels (green) in the inflamed ear skin of PBS (A) and AMD3100-treated (B) K14-VEGF-A transgenic mice. One ear
half is shown. Scale bar represents 100 mm. (C) Quantitative image analysis of MECA-32+ blood vessels (BV) revealed significantly reduced numbers of
blood vessels per millimeter basement membrane (BM) in the inflamed ear skin of AMD3100-treated mice, as compared with PBS-treated control
mice. (D–E) FACS analysis of CXCR4 expression by dermal blood vascular endothelial cells (BEC; D) and lymphatic endothelial cells (LEC; E) revealed
that CXCR4 is expressed by BEC but not by LEC in vitro. (F) Immunofluorescence staining for CXCR4 (red), von Willebrand factor (VwF, green) and
Podoplanin (Podo, purple) of inflamed ear skin (confocal image) demonstrates specific CXCR4 expression by blood vessels (BV) but not lymphatic
vessels (LV). Scale bar represents 20 mm. Data represent mean 6SD. *P,0.05.
doi:10.1371/journal.pone.0093665.g003
SDF-1/CXCR4 in Skin Inflammation
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Figure 4. Inhibition of SDF-1 signaling alleviates chronic skin inflammation and inhibits leukocyte migration towards SDF. (A) On
day -5, hemizygous K14 VEGF-A transgenic mice (n = 14) were sensitized with 2% oxazolone and challenged on day 0 with 1% oxazolone on the ears.
Starting 7 days after challenge, mice received i.v injections of anti-SDF-1 antibody or isotype-matched IgG every second day. (B) Neutralization of SDF-
1 (g) significantly reduced inflammatory ear swelling as compared with IgG-injected mice (%). Data represent mean 6SEM. (C-D) H&E stains of
mouse ear sections at day 21 showed reduced edema and inflammatory cell infiltration in the anti-SDF-1 treated mice (D) in comparison to the IgG
control group (C). One ear half is shown. Scale bar represents 100 mm. (E) In anti-SDF-1 treated mice, the weight of ear draining LNs was significantly
reduced compared with controls. (F-H) Immunofluorescence staining for CD68 revealed a significant reduction in the percentage of area covered by
macrophages in anti-SDF-1-treated animals as compared to IgG treatment. (I-L) Neutralization of SDF-1 decreased the size and numbers of blood
vessels in the inflamed ear skin. (M) FACS analysis of CD11b+ splenocytes revealed a clear expression of CXCR4 on their surface. (N) SDF-1 promoted
the chemotactic migration of CD11b+ splenocytes in vitro. (O-P) The chemotactic effect of SDF-1 was blocked by incubation with AMD3100 (O) or
with an anti-SDF-1 antibody (P), but not with control IgG. Two independent experiments were performed. Data represent mean6SD. **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0093665.g004
SDF-1/CXCR4 in Skin Inflammation
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analysis, these cells strongly express CXCR4 (Fig. 4M). We
found that SDF-1 dose-dependently induced chemotaxis of
CD11b+CXCR4+ splenocytes, with a minimal effective concen-
tration of 100 ng/ml (Fig. 4N). The number of migrated cells was
dose-dependently decreased when the cells were pre-incubated
with AMD3100. At a concentration of 10 mg/ml, AMD3100
completely blocked the chemoattractant effect of SDF-1 (Fig. 4O).
Addition of the anti-SDF-1 blocking antibody also significantly
decreased the amount of migrated cells in response to SDF-1 when
compared to control IgG (239.3%; P,0.001; Fig. 4P).
Blockade of the SDF-1/CXCR4 axis normalizes epidermal
architecture and decreases inflammatory cell infiltration
in inflamed skin
Characteristic features of human psoriasis are marked thicken-
ing of the epidermis, due to increased proliferation of keratinocytes
in the interfollicular epidermis, as well as abnormal terminal
differentiation of keratinocytes [2]. At day 21 (after 14 days of
treatment), control PBS-treated mice showed marked inflamma-
tory dermal infiltrates and epidermal thickening (Fig. 5A), many
numbers of BrdU-positive proliferating epidermal keratinocytes
(Fig. 5C), and strong expression of the proliferation marker keratin
6 (K6; Fig. 5E) and the terminal differentiation marker loricrin
(Fig. 5G). In contrast, AMD3100 treatment resulted in a reduction
of epidermal thickness and of dermal inflammatory infiltrates
(Fig. 5B, O). Also, the expression of keratin 6 and of loricrin was
reduced (Fig. 5F, H), and the number of proliferating intraepi-
dermal BrdU+ cells was significantly reduced (236%; P,0.01;
Fig. 5D, P).
Human psoriatic skin is also characterized by increased
numbers of CD4+ T-cells, dendritic cells and macrophages within
the dermis [2,3,33]. We next quantified the effect of CXCR4
blockade on the recruitment of macrophages into the inflamed ear
skin, using two different macrophage markers, F4/80 and CD68
(Fig. 5I–L). The percentage of tissue area covered by macrophages
was significantly reduced after AMD3100 treatment for both
macrophage markers (by 27 and 31% respectively, P,0.05;
Fig. 5Q-R). The infiltration of CD8+ T cells into the epidermis is a
key feature of human psoriasis and of chronic skin inflammation in
K14-VEGF-A transgenic mice [2,9]. We found that the number of
intraepidermal CD8+ cells was reduced by 33% (P,0.05) in the
AMD3100-treated mice, as compared with PBS-injected mice
(Fig.5 M–N, S). These results indicate that inhibition of the
CXCR4 receptor inhibits recruitment of inflammatory cells into
the inflamed skin.
To further corroborate these results and to study whether
neutralization of SDF-1 might also lead to comparable effects, we
next performed FACS analyses of distinct leukocyte subpopula-
tions that were isolated from the inflamed ear skin of AMD3100
and PBS-treated mice, and of anti-SDF-1 and control-IgG-treated
mice. All investigated inflammatory cell types (CD4+ and CD8+ T
cells, dendritic cells, CXCR4+ dendritic cells, macrophages and
CXCR4+ macrophages) were reduced after AMD3100 treatment
and also after anti-SDF-1 treatment, compared to control treated
mice (Fig. S1 in File S1).
Blockade of CXCR4 reduces psoriasis-like skin
inflammation induced by imiquimod
To investigate the role of the SDF-1/CXCR4 axis in a second
mouse model of psoriasis, we used the imiquimod-induced
psoriasis-like skin inflammation model [24,25].
Real-time RT-PCR analyses of mouse ear skin from uninflamed
and from imiquimod (IMQ)-treated mice (treatment for 8
consecutive days) revealed a significant increase in the expression
of CXCR4 (1.5-fold, P,0.05) and of SDF-1 (1.7-fold, P,0.01) in
the inflamed skin (Fig. 6A–B). CXCR7 was slightly downregulated
in the IMQ-inflamed skin compared to uninflamed skin (data not
shown). Immunofluorescence stainings demonstrated a higher
number of CXCR4 expressing cells in IMQ-inflamed skin than in
uninflamed skin (Fig. 6C–D). Quantitative image analyses revealed
that the percentage of tissue area that stained positively for
CXCR4 was significantly increased (347%, P,0.001) in the IMQ-
inflamed ear skin as compared with uninflamed skin (Fig. 6E).
Next, C57BL/6 wild-type mice were treated with s.c. injections
of AMD3100 every 12 hours. At 12 hours after the first injection,
an imiquimod (IMQ)-containing cream (Aldara) was topically
applied to the ear skin. IMQ was applied daily for 8 consecutive
days and the mice were analyzed at day 9 (Fig. 6F). AMD3100
treatment significantly reduced ear thickness (Fig. 6G) and
epidermal thickness (247%; P,0.001; Fig. 6H–J) in the ears, as
compared with control PBS-injected mice. The number of
proliferating epidermal keratinocytes was significantly reduced
after CXCR4 inhibition, compared to control treatment (248%;
P,0.01; Fig. 6K).
Stainings for the macrophage markers CD68 and F4/80
revealed a significant reduction of the positively stained skin area
(242%; P,0.01 and 236.7%; P,0.001; Fig. 7A–D, I–J). Antigen
presenting cells (MHCII+) were also significantly reduced upon
AMD3100 treatment (253.7%, P,0.001; Fig. 7E–F, K), whereas
no significant change was observed in neutrophil infiltration (Gr-
1+) between the two groups (data not shown).
As evaluated by staining for MECA-32, the number of
cutaneous blood vessels was significantly decreased in
AMD3100-treated mice, compared to control mice (238%;
P,0.05; Fig. 7G–H, L). The reduction of the cellular markers of
inflammation after CXCR4 blockade was in agreement with the
strongly decreased expression of the inflammatory markers
CXCL3, CCL20, S100a7 and S100a8 (Fig. 7M-P).
Discussion
In this study, we investigated the role of the SDF-1/CXCR4
axis in human psoriasis and in experimental chronic skin
inflammation. Using a VEGF-A driven mouse model of cutaneous
inflammation, we found that inhibition of CXCR4 by AMD3100,
a specific CXCR4 antagonist, as well as neutralization of its ligand
SDF-1 significantly improved the course of chronic skin inflam-
mation. The anti-inflammatory effect of AMD3100 was further
confirmed in a second, the imiquimod-induced model of skin
inflammation.
Our findings of increased numbers of CXCR4+ cells in human
psoriatic skin lesions are in line with the observed upregulation of
CXCR4 and SDF-1 mRNA expression in psoriatic skin [21,22]
and with the detection of SDF-1 protein in psoriatic lesions [23]. It
is of interest that increased numbers of CXCR4+ leukocytes have
also been recently detected in other chronic inflammatory diseases,
namely in the synovia of joints affected by rheumatoid arthritis
and in the colonic tissue of patients with ulcerative colitis patients
[34,35]. Indeed, inhibition of CXCR4 was found to exert anti-
inflammatory effects in experimental models of joint inflamma-
tion, colitis and allergic lung inflammation [28,36]. Accordingly,
increased expression of the CXCR4 ligand SDF-1 has also been
reported in murine experimental colitis and collagen-induced
arthritis, as well as in the synovial fluid of rheumatoid arthritis
patients [34,35,37].
Importantly, in the present study, we found that both CXCR4
and SDF-1 were also upregulated in two independent experimen-
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tal mouse models of chronic, psoriasis-like skin inflammation,
namely the chronic skin inflammation induced in K14-VEGF-A
transgenic mice [9,10] and the cutaneous inflammation induced
by topical treatment of mouse skin with imiquimod [24,25]. In the
VEGF-A transgenic model, dermal endothelial cells expressed
increased levels of CXCR4, in line with the experimental
upregulation of endothelial CXCR4 expression by VEGF-A in
vitro [16]. The second receptor for SDF-1, CXCR7, has recently
been described as a scavenger for SDF-1, and it has been
suggested that ligand internalization and degradation by CXCR7
limits the availability of SDF-1 and thereby modulates the activity
of CXCR4 [38]. It is therefore of interest that the CXCR7
expression was slightly decreased in the inflamed ear skin of both
mouse models, suggesting that both upregulation of CXCR4 and
downregulation of CXCR7 contribute to the pro-inflammatory
effect of SDF-1 in chronically inflamed skin.
In the K14-VEGF-A transgenic mouse model, VEGF-A
expression is strongly increased in the inflamed skin [39] and
Figure 5. Inhibition of CXCR4 reduces inflammatory cell infiltration into the skin and normalizes epidermal architecture. (A–B) H&E
stains of ear skin sections at day 21 showed that AMD3100 treatment reduced edema formation, epidermal thickening and inflammatory cell
infiltration. (C–D) CXCR4 inhibition reduced the number of intraepidermal BrdU+ proliferating cells in the inflamed ear skin. (E–H) The
hyperproliferation-associated keratin 6 and loricrin, a marker of terminal epidermal differentiation, were less broadly expressed in the epidermis of
AMD3100-treated mice than in PBS-treated mice. (I–L) Immunofluorescence staining of the two macrophage markers F4/80 and CD68 revealed a
significant reduction in the percentage of area covered by macrophages in AMD3100-treated mice compared to PBS treatment. (M–N) Inhibition of
CXCR4 decreased the number of intraepidermal CD8+ T-cells in the inflamed ear skin. One ear half is shown. (O–P) Computer-assesed quantification of
epidermal thickness (O), number of intraepidermal BrdU+ cells (P), the percentage of covered area by F4/80 (Q) and CD68 (R) postitive macrophages
and the number of intraepidermal CD8+ cells (S). Scale bars represent 100 mm. Data represent mean 6SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0093665.g005
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represents the major driver of inflammation-induced angiogenesis.
VEGF-A binds to its high-affinity receptors VEGFR-1 and
VEGFR-2, and we have previously found that inhibition of these
two receptors by NVP-BAW2881, a VEGFR tyrosine-kinase
inhibitor, exerts strong anti-inflammatory effects by reducing the
number of infiltrating leukocytes and of blood vessels in the
inflamed ear skin [11]. Furthermore, anti-VEGF-A antibody
treatment strongly reduced skin inflammation, as well as the
number and size of blood vessels, in a mouse model in which
epidermal-specific deletion of c-Jun and JunB leads to a psoriasis-
like skin inflammation [12]. These results indicate an important
role of angiogenesis in the mediation of chronic skin inflammation.
It is therefore of interest that we found CXCR4 to be specifically
expressed by cultured dermal blood vascular endothelial cells but
not lymphatic endothelial cells, and that CXCR4 was expressed by
the small cutaneous blood vessels but not by lymphatic vessels in
inflamed skin in situ. Importantly, our findings reveal, for the first
time, that inhibition of CXCR4 reduces inflammation-induced
angiogenesis, as shown in two independent mouse models, and
they identify blood vessels as important targets of AMD3100. The
involvement of CXCR4 in inflammatory angiogenesis is further
supported by the reported activity of SDF-1 on in vitro tube
formation, migration and sprouting of endothelial cells, all
essential steps in the formation of new blood vessels, and on the
in vivo angiogenic activity of SDF-1 in cutaneous and cornea
assays [15,16]. Even tough, inflammatory angiogenesis is likely to
be an attractive target for the treatment of chronic skin
inflammation, there is some evidence, that severe psoriasis is
Figure 6. Inhibition of CXCR4 reduces imiquimod-induced skin inflammation. (A, B) Real-time RT-PCR analysis of extracts of IMQ-inflamed
ear skin (8 consecutive days) and non-inflamed skin (n = 5 per group). The expression of CXCR4 and SDF-1 was significantly upregulated in IMQ-
treated ear skin compared to uninflamed skin. (C–E) Immunofluorescence stains of ear skin for CXCR4 revealed a significantly increased CXCR4+ tissue
area in IMQ-treated mice as compared with uninflamed skin. (F) Mice (n = 5 per group) received AMD3100 or PBS injections every 12 hours. 12 hours
after the first injection, IMQ was applied topically, followed by daily applications for 8 days. (G) Treatment with AMD3100 (g) significantly reduced ear
swelling as compared with PBS-treated controls (%). (H–J) H&E stains of ear skin sections showed that AMD3100 treatment (I) significantly reduced
epidermal thickening compared to PBS-treated mice (H). Scale bar represents 100 mm. (K) CXCR4 inhibition significantly reduced the number of
intraepidermal BrdU+ proliferating cells in the inflamed ear skin, as compared with control mice. Data represent mean6SD. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0093665.g006
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associated with a significant increase in cardiovascular diseases as
compared to mild psoriasis and healthy individuals [40]. Thus, for
systemic therapies with anti-angiogenic actions, high-risk cardio-
vascular patients would most likely have to be excluded.
AMD3100 has been described as specific CXCR4 antagonist
[26]. To further investigate the potential role of the SDF-1/
CXCR4 axis in inflammation, we performed a range of in vitro
and in vivo studies using a neutralizing anti-SDF-1 antibody.
These studies confirmed the important role of SDF-1-mediated
CXCR4 activation in promoting chronic skin inflammation
interaction and therefore validate the specific inhibition of the
SDF-1/CXCR4 as a new therapeutic strategy to treat chronic
inflammatory skin diseases.
Our results indicate that SDF-1 attracts CD11b+ splenocytes in
a dose-dependent manner in vitro and that AMD3100 and anti-
SDF-1 antibody block SDF-1 induced migration, in agreement
with the reported chemoattractive activity of SDF-1 for mononu-
clear cells and different lymphocyte subpopulations in vitro and in
vivo [41,42]. Importantly, both AMD3100 and the SDF-1
blocking antibody also significantly reduced the number of
different inflammatory cell subtypes in the inflamed ear skin in
vivo. Together with the increased SDF-1 expression in the
inflamed skin of K14-VEGF-A transgenic mice and of IMQ-
treated mice, these data suggest that circulating CXCR4+
inflammatory cells are chemoattracted to the inflamed cutaneous
tissue by SDF-1 and that this chemoattraction can be blocked by
inhibiting the SDF-1/CXCR4 axis. Indeed, FACS analyses
revealed reduced numbers of recruited CXCR4+ dendritic cells
and CXCR4+ macrophages in the inflamed ear skin of K14-
VEGF-A transgenic mice after either anti-SDF-1 or AMD3100
treatment.
Figure 7. CXCR4 inhibition reduces inflammatory cell infiltration, angiogenesis and inflammatory marker expression in the
imiquimod-induced skin inflammation. (A–H) Representative images of immunofluorescence stains for CD68+ (A, B) and F4/80+ (C, D)
macrophages, MHCII+ antigen presenting cells (E, F) and MECA-32+ blood vessels (G, H) in the IMQ-inflamed ear skin of PBS and AMD3100-treated
mice. One ear half is shown. Scale bars represent 100 mm. (I–K) Quantitative image analysis showed a significant reduction in the percentage of area
covered by macrophages (I, J) and antigen presenting cells (K) in AMD3100-treated mice. (L) Inhibition of CXCR4 decreased the number of Meca-32+
blood vessels (BV). (M–P) Real-time RT-PCR analyses of RNA from whole ear skin extracts of imiquimod-inflamed mice showed a significant
downregulation of CXCL3 (M), CCL20 (N), S100a7 (O) and S100a8 (P). Data represent mean 6SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0093665.g007
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It is of interest that inhibition of CXCR4 largely normalized all
of the major pathological parameters of psoriatic skin lesions. Our
findings indicate that blood vessels and several types of inflam-
matory cells are direct targets of SDF-1/CXCR4 axis inhibition,
whereas epidermal normalization resulted most likely from the
overall reduced inflammatory response. One has to keep in mind
that psoriasis is a human-specific disease which is not naturally
observed in animals, and that most experimental mouse models do
not fully recapitulate all characteristics of the human disease,
indicating that it might be advantageous to use more than just one
mouse model for specific pathogenic studies of psoriasis. The K14-
VEGF-A transgenic mouse model of chronic cutaneous inflam-
mation shares several of the major characteristic histological
features of human psoriatic skin. These include acanthosis of the
epidermis, increased epidermal proliferation and abnormal
differentiation, pathological angiogenesis and leukocyte infiltration
with preferential location of CD8+ T cells in the epidermis and of
CD4+ T cells in the dermis. Nevertheless, given the above
mentioned concerns regarding mouse models of psoriasis, we
investigated the role of the SDF-1/CXCR4 axis in a second mouse
model of psoriasis, namely the IMQ-induced skin inflammation
model. Importantly, these studies confirmed the findings of the
VEGF-A transgenic mouse model, indicating that specific
inhibition of the SDF-1/CXCR4 might represent a new
therapeutic strategy to treat skin inflammation. In light of the
potential adverse effects of systemic AMD3100 treatment, which
include thrombocytopenia observed in HIV-infected patients [43],
the development of topical anti-SDF-1/CXCR4 therapies might
represent a more promising avenue for inhibiting chronic
inflammatory skin disorders such as psoriasis.
Supporting Information
File S1 Figure S1, Inhibition of the SDF-1/CXCR4 axis
decreases the number of several types of inflammatory cells in
chronically inflamed skin. Single-cell suspensions from inflamed
ear skin were analyzed by FACS for the presence of different
inflammatory cell populations. (A, B) Inflamed ear skin was
analyzed for the presence of CD3+/CD4+ and CD3+/CD8+ T-
cells. AMD3100 and anti-SDF-1 treatment significantly decreased
the number of CD4+ cells, as compared with control mice.
Compared to PBS-treated mice, AMD3100 further significantly
decreased the number of CD8+ cells in the inflamed ear skin. Anti-
SDF-1 showed the same tendency. (C, D) The number of dendritic
cells (DC) was investigated by analyzing I-A/I-E+CD11c+ cells.
Inhibition of the SDF-1/CXCR4 axis resulted in significantly
reduced numbers of DC in the inflamed ear skin. Anti-SDF-1
treatment also significantly decreased the number of CXCR4+
DC. AMD3100 treatment showed the same trend. (E, F)
Macrophages were assessed by evaluating the CD11b and F4/
80 double positive population within live CD45+ leukocytes.
AMD3100 significantly reduced the number of macrophages as
well as of CXCR4+ macrophages in the inflamed ear skin. Anti-
SDF-1 showed a tendency to reduce the number of these
inflammatory cell populations and significantly reduced the
number of CXCR4+ macrophages in the inflamed ear skin.
n = 5 per group. Two independent experiments were performed.
Data represent mean 6SD. *P,0.05; ***P,0.001. ns, not
significant.
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